Direct costs of chronic obstructive pulmonary disease among managed care patients.
about
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the TrendComputer-aided diagnosis of pneumonia in patients with chronic obstructive pulmonary disease.Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients.The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, CanadaVulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study.Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trialSimvastatin for the prevention of exacerbations in moderate-to-severe COPDA novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009.Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD.Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real worldRAGE and tobacco smoke: insights into modeling chronic obstructive pulmonary disease.Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: a cross-sectional study.Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.Vulnerability of patients with chronic obstructive pulmonary disease according to gender in China.Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease.Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four citiesHospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.COPD management costs according to the frequency of COPD exacerbations in UK primary care.Exercise for patients with COPD: an integral yet underutilized intervention.Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.Chronic obstructive pulmonary disease in African- and European-American women: morbidity, mortality and healthcare utilization in the USA.Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies.Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.Web-based Health Information Seeking and eHealth Literacy among Patients Living with Chronic Obstructive Pulmonary Disease (COPD).Associations between physical activity and 30-day readmission risk in chronic obstructive pulmonary disease.Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Study on drug costs associated with COPD prescription medicine in Denmark.RAGE signaling by alveolar macrophages influences tobacco smoke-induced inflammation.Proteases and Their Inhibitors in Chronic Obstructive Pulmonary DiseaseFactors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record dataEosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec, Canada
P2860
Q27026708-DAFD9AB5-4E7D-4EBE-B936-46C8C043AF6AQ30437561-65A269BB-21A2-41F7-BBD1-26DD6C55A38AQ31003434-EB4375A7-87F4-40E8-8BEB-7948526D8852Q31075146-E017A4DA-6DA8-4ED5-B8EE-7017C514280CQ33817770-B6D50CD0-EE92-45D8-A84C-9C242AD6208CQ33868106-E1B0A1A7-0B99-4196-B52B-26D99533ABBCQ34240886-37FBA2C1-28A5-4AAB-9FAD-ED2C55C14382Q34622570-B43513A5-E7E7-4334-BF40-19E60C28DF06Q34661935-EF620A93-0F24-4E0C-A166-B15920836733Q35096997-62B46FFA-8422-41CF-A76C-C06786D3A414Q35194591-0FDADD87-5C8F-4823-9C5D-B153DC042D5BQ35508638-A0DC8FC5-9392-49E8-B0D6-AB9D98A9BFC0Q35672836-F4EA4810-BB44-47B2-81CB-63E5DA3A8A43Q36025745-17BEEDD3-D028-4598-886A-6306B919FA40Q36156113-F5AE6E7B-1133-4ED6-8669-D3D81F946A7DQ36193793-9F3B86A8-5B85-4580-947B-7617330A3689Q36220088-40DD9CDB-3217-4548-8284-07F3D545D1E3Q36394339-427EEA97-B256-4615-AE6D-8F2F21D7C573Q36493552-F387F186-DC2E-4293-B305-ABF041C87D94Q36732324-EA046434-F23E-4D3E-B9AF-7039AE95F8C9Q36945570-603C8E4E-D814-430B-A025-5D5E616F3624Q37003149-E62A3572-FF20-4AA5-A5CB-2EB3F3F9714FQ37365503-5812FE86-94AF-4E83-B78A-4FFAB92A02A0Q37380396-B18A87AB-D930-4FC6-A7ED-AB368F58134DQ37473344-812CE4EB-78AC-4AD8-8EC5-99ADE096B384Q38085131-9657D04F-67E9-4225-9B39-6127B3AA5392Q38317463-45450510-0141-4603-AEB6-4EF3F01D926DQ38363934-361ACDD7-A519-42E2-8973-0BE95F05DA7AQ39458622-BDBDE731-92BA-4C2F-A63D-57064B21F7B0Q39649096-0B14B936-611F-40A6-B234-AA9C5D4B1E4BQ43781923-51E20E05-5591-47F8-A8C8-FDEC21584511Q45182538-0096A4D0-FE28-4D1F-A4DA-DC9C2B4ECDADQ46824448-9DAE7D11-3703-41F7-AAA1-BAB04ED558E1Q47289066-8E2BA70F-D010-4E88-A5B1-051E230C842DQ47966525-D7DB823A-0B3D-41D8-B684-A6D7CA4A1905Q51198516-18329C76-B5C1-4272-B614-A0A7E004DC0BQ51793428-AE6254C7-B7B7-497D-AAA8-027F8CDBB418Q57167213-CAEC2B5B-B31E-4865-9C86-5642D18E46ACQ57815419-497E5D1E-9D4E-497B-A101-599DA793AD89Q57817679-1B86B79A-D8D7-4132-BE28-88F20D75437D
P2860
Direct costs of chronic obstructive pulmonary disease among managed care patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@ast
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@en
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@nl
type
label
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@ast
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@en
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@nl
prefLabel
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@ast
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@en
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@nl
P2093
P2860
P356
P1476
Direct costs of chronic obstructive pulmonary disease among managed care patients.
@en
P2093
Anand A Dalal
Aylin A Riedel
Laura Christensen
P2860
P304
P356
10.2147/COPD.S13771
P407
P577
2010-10-05T00:00:00Z